Real-World Performance of the MiniMed 780G Advanced Hybrid Closed-Loop System in the Middle East, North Africa, and...

Real-world evidence (RWE) data on the use of automated insulin delivery (AID) systems in the MENAT region (Middle East, North Africa, Türkiye) are limited. The aim of this article is to report RWE data on the use of the MiniMed™ 780G AID system in MENAT.

CareLink™ personal data as of July 01, 2024, of MENAT users from countries with more than 25 users were included. Continuous glucose monitoring-based endpoints, system usage, and insulin delivery were examined in (1) the overall cohort, (2) users who reached 12 months of system use (longitudinal cohort), and (3) users having pre- to post-AHCL (advanced hybrid closed-loop) algorithm initiation data.

Seven thousand nine hundred and sixty-five users across 19 MENAT countries showed a mean glucose management index (GMI) of 6.9 ± 0.7%, time in range (TIR) of 71.7 ± 18.2%, time in tight range (TITR) of 48.9 ± 19.4%, time below range 70 mg/dL of 2.4 ± 3.9%, and time below range 54 mg/dL of 0.5 ± 1.7%. TIR and TITR were higher in users using optimal settings (glucose target = 100 mg/dL and an active insulin time = 2 h), being 76.3 ± 16.4% and 54.2 ± 18.8%, respectively. Consistent results were obtained analyzing different age groups, different countries, across the four seasons, between weekday/weekends, and day/night. Glycemic improvements began after AHCL algorithm initiation and sustained for 12 months, with a TIR and TBR70 that reached international targets in all months.

MiniMed 780G system RWE data in the MENAT region showed a sustained glycemic control that achieved international target criteria across different age groups, countries, and climate extremes. These findings align with RWE data from other geographies, validate the broad applicability of the MiniMed 780G benefits, and may help expand access to AID systems in the region.